Drug Discovery 2017
March 27 - 28, 2017 - LONDON UK
SMi is proud to invite you to its exclusive conference on Drug Discovery, taking place on the 27th & 28th March 2017 in London. The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. Against this backdrop Drug Discovery 2017 will provide a platform to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges. WHY YOU CAN'T MISS DRUG DISCOVERY 2017 * AstraZeneca discusses the use of CRISPR/Cas9 Technology in target discovery, hit finding and translational studies * Novartis optimises the success of phenotyping screening * Takeda explores whether translational medicine is capable of increasing success rate in pharma * Gain insights into receptor activation from agonist and antagonist structures with Merck * Discover applications of enabling chemistry technology to the acceleration of the drug discovery process with AbbVie LEARN FROM THE EXPERTS Bringing together industry leaders who will highlight future opportunities for novel therapeutic discovery, don't miss out on presentations from our featured speakers including: * Lorenz Mayr, VP & Global Head, AstraZeneca * Guido Hanaeur, Scientific Director Translational Medicine, Takeda * Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis * Yolanda Chong, Principal Scientist, Johnson & Johnson * Matthias Frech, Director, Molecular Interactions & Biophysics, Merck Serono * Wengard Czechtizky, Head of Chemistry, Sanofi * Stephen Pickett, Senior Scientific Investigator, GSK ...plus case studies from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares and more!